Table 1.
Baseline characteristics, clinical presentation and medications in patients IMR and anterior or inferior STEMI
| Variable | Anterior STEMI | Inferior STEMI | p Value |
|---|---|---|---|
| Number | 302 | 503 | <0.01 |
| Grades of MR | 1+57% 2+30.5% 3+11.3% 4+1.3% |
1+50.7% 2+33.4% 3+11.3% 4+4.6% |
0.5 |
| Age (year) | 66.6±13 | 65±12.6 | 0.8 |
| Sex (male, %) | 53.6% | 60.2% | 0.7 |
| Diabetes mellitus | 30.8% | 27.8% | 0.4 |
| Hypertension | 74.6% | 73.6% | 0.8 |
| Renal impairment | 10.6% | 7.6% | 0.2 |
| Atrial fibrillation | 21.5% | 25.8% | 0.2 |
| COPD | 9.5% | 11.3% | 0.5 |
| PAD | 9.6% | 10.2% | 0.8 |
| BMI (kg/m2) | 27.8±6 | 28.3±6 | 0.3 |
| Obese (BMI>30 kg/m2) | 28% | 30.1% | 0.5 |
| Stroke | 11.7% | 8.6% | 0.2 |
| Current smoker | 28.5% | 27.4% | 0.7 |
| Prior MI | 35.3% | 35.8% | 0.9 |
| History of CABG | 10.3% | 19.3% | 0.007* |
| Heart rate | 85±17 | 79±19 | 0.07 |
| Systolic blood pressure | 122±27 | 123±24 | 0.4 |
| NYHA | I 60.3% II 6.6% III 6.3% IV 26.8% |
I 62.2% II 2.8% III 5.7% IV 29.3% |
0.1 |
| Shock | 15.9% | 11.1% | 0.06 |
| IABP | 27.5% | 17.3% | 0.0009* |
| Number of diseased vessels | 1=56.5% 2=24.3% 3=19.3% |
1=60.7% 2=19% 3=20.4% |
0.2 |
| HB at baseline: median (IQR) | 13 (12–15) | 13.6 (11.7–14.8) | 0.9 |
| Anaemia (HB<12) | 25% | 27.7% | 0.5 |
| Peak of total CK: median (IQR) | 1319 (5 022 947) | 1417 (6 702 633) | 0.9 |
| Peak of CK-MB: median (IQR) | 136 (39 306) | 139 (57 281) | 0.9 |
| ACE inhibitor (before admission) | 12.3% | 16.8% | 0.1 |
| Aspirin (before admission) | 83.2% | 84.5% | 0.7 |
| β-blocker (before admission) | 27.1% | 29.7% | 0.5 |
*values have reached statistical significance.
BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; HB, haemoglobin; IABP, intra-aortic balloon pump; IMR, ischaemic mitral regurgitation; MI, myocardial infarction; MR, mitral regurgitation; NYHA, New York Heart Association class; PAD, peripheral arterial disease; STEMI, ST elevation myocardial infarction.